CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a�Type II variation application�to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback